Osivax is a clinical-stage biotechnology company developing a pipeline of vaccines and immunotherapies. Its flagship vaccine, OVX836, comprises a protein engineered to include the natural NP from an A-strain virus and the company’s proprietary oligoDOM® technology, an auto-assembling structure with a positively-charged tail that creates a large protein nanoparticle with multiple copies of the antigen. This proprietary structure facilitates the uptake into dendritic cells and increases the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation.